Last reviewed · How we verify
NCT05813067
Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women
NA trial testing JDS-HF 3.0 in Vasomotor Symptoms in 74 participants. Completed in 23 April 2024.
23 April 2024
Quick facts
| Lead sponsor | Bonafide Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 74 |
| Start date | 27 December 2022 |
| Primary completion | 23 April 2024 |
| Estimated completion | 23 April 2024 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- JDS-HF 3.0
- Placebo
Conditions studied
- Vasomotor Symptoms — all drugs for Vasomotor Symptoms →
- Postmenopausal Disorders — all drugs for Postmenopausal Disorders →
Sponsor
Bonafide Health — full company profile →
Who can join
Adults 40 to 65, female only, with Vasomotor Symptoms or Postmenopausal Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The role of nutrition is recognized as a vital component to healthy aging throughout menopause. The goal of this study is to evaluate a dietary supplement for its safety and effects on vasomotor symptoms in menopausal women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05813067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vasomotor Symptoms
Currently open trials in the same condition.
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07112651 — Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause · NA · recruiting
- NCT07042516 — Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). · Phase 2 · recruiting
- NCT06628388 — Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong · NA · recruiting
Other Bonafide Health trials
Trials by the same sponsor.
- NCT07453693 — An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement · NA · recruiting
- NCT07408115 — Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women · NA · completed
- NCT07375095 — A Study of a Sleep Supplement to Improve Sleep in Women Going Through Menopause · NA · completed
- NCT06289907 — Hot Flash and Night Sweat Virtual Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05813067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bonafide Health
- Last refreshed: 26 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05813067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing